Researchers sought to determine whether palliative care was different for patients with hematological malignancies than for those with other malignancies.
Researchers sought to determine whether combining melflufen with dexamethasone would be safe and effective in patients with relapsed/refractory multiple myeloma with extramedullary disease.
Researchers sought to determine whether a triplet regimen of melflufen, dexamethasone, and bortezomib would be safe in patients with relapsed/refractory multiple myeloma.
